Recurrent or Refractory Pediatric Ependymoma
1 competing product in clinical development for Recurrent or Refractory Pediatric Ependymoma.
Pipeline by Phase
Phase 21
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| erlotinib + etoposide | Astellas Pharma | Phase 2 | Terminated | 27 |